Lord Abbett & CO. LLC cut its stake in shares of Spark Therapeutics Inc (NASDAQ:ONCE) by 33.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 66,423 shares of the biotechnology company’s stock after selling 33,561 shares during the period. Lord Abbett & CO. LLC owned about 0.18% of Spark Therapeutics worth $2,600,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Pearl River Capital LLC purchased a new position in shares of Spark Therapeutics in the fourth quarter valued at about $31,000. Quantamental Technologies LLC purchased a new position in shares of Spark Therapeutics in the fourth quarter valued at about $126,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Spark Therapeutics by 16.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,460 shares of the biotechnology company’s stock valued at $135,000 after acquiring an additional 485 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in shares of Spark Therapeutics by 103.4% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,718 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 1,890 shares in the last quarter. Finally, Shell Asset Management Co. purchased a new position in shares of Spark Therapeutics in the third quarter valued at about $208,000.
Shares of ONCE stock opened at $113.00 on Friday. Spark Therapeutics Inc has a 12-month low of $34.53 and a 12-month high of $114.20. The company has a current ratio of 9.10, a quick ratio of 8.68 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $4.29 billion, a PE ratio of -53.55 and a beta of 2.59.
Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, February 19th. The biotechnology company reported ($1.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by ($0.89). Spark Therapeutics had a negative return on equity of 14.94% and a negative net margin of 121.78%. The firm had revenue of $13.15 million during the quarter, compared to the consensus estimate of $26.76 million. During the same period last year, the firm posted ($1.63) earnings per share. The company’s revenue for the quarter was up 47.9% compared to the same quarter last year. As a group, analysts predict that Spark Therapeutics Inc will post -4.52 EPS for the current year.
Several equities analysts have recently commented on ONCE shares. Cantor Fitzgerald restated a “buy” rating and issued a $80.00 price objective on shares of Spark Therapeutics in a research report on Sunday, February 17th. Credit Suisse Group restated a “hold” rating and issued a $44.00 price objective on shares of Spark Therapeutics in a research report on Friday, February 8th. William Blair restated a “buy” rating on shares of Spark Therapeutics in a research report on Tuesday, February 19th. Raymond James restated a “buy” rating on shares of Spark Therapeutics in a research report on Monday, November 26th. Finally, Mizuho downgraded Spark Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, February 25th. Seventeen investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $77.26.
WARNING: “Lord Abbett & CO. LLC Has $2.60 Million Position in Spark Therapeutics Inc (ONCE)” was published by Highlight Press and is the sole property of of Highlight Press. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://highlightpress.com/2019/03/23/lord-abbett-co-llc-has-2-60-million-position-in-spark-therapeutics-inc-once.html.
Spark Therapeutics Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.
Recommended Story: What are the advantages of the Stochastic Momentum Index?
Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.